the specific objectives of this funding opportunity are to:

• facilitate and support a national collaborative hepatitis c public health research program that aligns with the with the government of canada five-year action plan on stbbi and that links and leverages existing networks and research programs, engages knowledge users, people with living/lived experience and decision makers to:
  • enable innovative, high quality, collaborative research in the area of prevention of hepatitis c infection and reinfection, linkage to care in priority populations and hepatitis c-related health complications;
  • accelerate the translation and uptake of knowledge and implementation of evidence to inform practices, policies and programs through models of integrated knowledge translation and innovative strategies that engage knowledge users, people with living/lived experience and decision makers;
  • develop and/or strengthen innovative multidisciplinary curricula and training opportunities for 世界杯2022赛程表淘汰赛 and professionals.

the objectives of stream 1 are:

• accelerate rapid research on sars-cov-2 variants in canada to contribute to the national and global efforts to address sars-cov-2 variants; and
• generate timely evidence on sars-cov-2 variants that will show impact within 3-6 months and is relevant to biological, clinical, health system, and public health strategies.

stream 1 applicants are strongly encouraged to consider maximizing impact by outlining how they intend to participate in:

1. the formation of a network (stream 2) or participating in a network formed by another npa (stream 2); and,
2. the cihr network for emerging variants research once established.

the objective of stream 2 is to:

• establish interdisciplinary networks that contribute to the rapid response, understanding, and coordination of sars-cov-2 variants research.

stream 2 applicants are strongly encouraged to consider maximizing impact by ensuring that the networks are inclusive of research from across pillars/research areas. applicants are also expected to ensure that the network has appropriate and diverse representation within the team (see equity, diversity, and inclusion expectations below).

the networks formed through stream 2 are expected to build the foundation of the cihr network for emerging variants research.

please note that stream 2 npas interested in forming a network are strongly encouraged to indicate their intent to do so and area(s) of focus through cihr’s linkage tool. stream 2 npa’s are also encouraged to use the linkage tool to collaborate with researchers interested in participating in networks (including those not funded through cihr covid-19 competitions).

cihr is committed to promoting the inclusion and advancement of groups underrepresented in science as one of the means to enhance excellence in research, training and knowledge translation. cihr’s position on equity, diversity and inclusion (edi) is available in the tri agency statement on equity, diversity and inclusion. stream 2 applications must clearly describe the research team’s commitment to engaging a diversity of members, in particular related to how they will address team composition and recruitment processes; research environment; training activities; and/or knowledge translation activities, as applicable. additional guidance can be found on the best practices in equity, diversity and inclusion in research webpage.

when completing the application, applicants must protect the privacy and confidentiality of all team members. how an individual self-identifies is personal and confidential information, which should not be disclosed without consent.

note: successful stream 1 and stream 2 applicants will be connected to a surveillance network that will coordinate access to the repository of variants as available and as required.

applications must ensure relevance to all objectives:

• to enable a comprehensive and timely understanding of the biological, clinical, social, and population health implications of emerging sars-cov-2 vocs and their relevance for public health, health systems and policy through the establishment of an interdisciplinary cihr network for emerging variants research;
• to provide an integrated platform within canada to coordinate across different research areas that focus on emerging vocs research through coordination across different disciplines and pillars of research and integrating surveillance efforts through a sustained collaboration/partnership with the vocn and other relevant local, national, and international partners; and
• to swiftly provide high-quality and real-time data on urgent and emerging research priorities in support of canada rapid response to emerging sars-cov2 variants, through building and activating as needed, a rapid response capacity in canada which can coordinate and conduct all aspects of voc related research.

key design components

the cihr network for emerging variants research funded through this call must expand existing national networks, infrastructures and relationships with local and international partners in order to leverage efforts and increase timeliness, efficiency, and impact of research on the emergence of sars-cov-2 vocs. the areas listed below are key design components for the network:

• governance: a plan for enhancing coordination and engagement among and with the existing networks and organizations to maximize research impact. this should include but not be limited to the vocn, the emerging and existing variants related research networks, and other relevant local, national, and international partners. the governance plan should ensure a mechanism for establishing an ongoing research priority-setting process, including to timely inform how and when the rapid response capacity will be activated to swiftly respond to emerging research priorities, while engaging key stakeholders across sectors. the governance plan should include concrete strategy for integration of external advice, including from the leadership committee that is being formed by cihr and other federal partners on the overall canadian strategy for variant response, and to ensure the cihr network for emerging variants research governance and research upholds principles of equity, diversity and inclusion.
• interdisciplinary approach: the cihr network for emerging variants research will build upon interactions with existing national and provincial networks and initiatives, and through the inclusion of the new networks emerging from other arms of cihr’s sars-cov-2 variant research response (cihr supplement stream 2) to address the issue of emerging voc through an integrated interdisciplinary approach. the individual teams and networks that get integrated into the national network may span a broad range of research areas and pillars and may include, but not limited to, in silico modelling, functional genomics, in vitro and in vivo characterization, immunological and vaccine protection assessment, and health systems, public health and social policy impacts.
• resource and data sharing: a plan for active collaboration and coordination across member networks to ensure resources are in place within member networks to support objectives of the funding. this plan should include strategies to enable and accelerate data and samples sharing, and increase efficiencies in research related processes, including but not limited to ethics review; contracts; sharing agreements; common protocols. this should also include a plan for applying the fair principles (findable, accessible, interoperable, reusable) to the data management strategy. the global indigenous data alliance (gida) care principles (collective benefit, authority to control, responsibility and ethics) should be integrated to aspects pertaining to indigenous data governance
• international linkages: a plan for liaison activities with like-minded international networks (e.g., those supported through gisaid) and consortiums (e.g., cog-uk, spheres) focused on sars-cov2 variants research and their biological, health system and public health implications to maximize the impact and international visibility of the cihr network for emerging variants, and reduce duplication of efforts internationally.
• patient and citizen engagement: the cihr network for emerging variants research must include meaningful mechanisms for patients/citizens/informal care providers' engagement in core activities and governance.
• indigenous network: the cihr network for emerging variants research must show a plan on how it will work collaboratively with the indigenous variants network.
• capacity building at a pan-canadian level: the cihr network for emerging variants research will play a facilitation and coordination role, adding a multidisciplinary, inter-professional, and cross-jurisdictional element to research training and mentorship activities in sars-cov2 variants research.
• knowledge mobilization: in collaboration with network partners and existing canadian networks, the cihr network for emerging variants research will provide a plan to mobilize knowledge being generated within and across the members to maximize the impacts of research.

applicants must submit an expression of interest (eoi) by email to ehtrf-frnms@cihr-irsc.gc.ca no later than 8:00 p.m. (est) on february 18, 2021. note that this task is mandatory to be eligible to submit a full application.

bell is committed to continued support for post-secondary student mental health and wellness across canada. bell let’s talk funding enabled the creation of the national standard of canada for mental health and well-being for post-secondary 世界杯2022赛程表淘汰赛  (the standard), under the leadership of the mental health commission of canada (mhcc) and in partnership with the canadian standards association (csa).

bell is building on this commitment to support student success with the creation of the bell let’s talk post-secondary fund. the post-secondary fund will include two initiatives to support post-secondary institutions in their journey to implement the standard. the first funding initiative to be made available is the bell let’s talk post-secondary fund kickoff grant.

in 2021, 100 kickoff grants are available to eligible canadian publicly funded post-secondary institutions. the one-time $25,000 kickoff grant supports research and other activities that institutions undertake to begin their journey to align with the standard. the period for submitting an application for a kickoff grant is open to february 26.

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

subject to the fy21 congressional appropriation for lcrp funding, fy21 lcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.    

applications submitted to the fy21 lcrp must address one or more of the following areas of emphasis:

• identify innovative strategies for prevention of the occurrence of lung cancer.
• identify innovative strategies for the screening and early detection of lung cancer.
• understand the molecular mechanisms of initiation and progression to lung cancer.
• understand contributors to lung cancer development other than tobacco.
• identify innovative strategies for the treatment of lung cancer.
• identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
• develop or optimize prognostic or predictive markers to assist with therapeutic decision-making.
• understand mechanisms of resistance to treatment (primary and secondary).
• identify innovative strategies for lung cancer care delivery (clinical management/surveillance/symptom management).
• understand factors that contribute to the health disparities in lung cancer, such as biological contributors; environmental, social, and cultural factors; and access to health care.

https://cdmrp.army.mil/funding/lcrp

concept award – letter of intent due april 6, 2021

all investigators at or above the level of postdoctoral fellow (or equivalent)

• supports highly innovative, untested, potentially groundbreaking concepts in lung cancer.
• emphasis on innovative concept or untested theory.
• research involving human subjects or specimens must be either exempt under title 32, code of federal regulations (cfr), part 219, section 104(d)(32 cfr 219.104[d]) or eligible for expedited review (21 cfr 56.110).
• clinical trials not allowed.
• preliminary data discouraged (not consistent with intent of award mechanism).
• military relevance strongly encouraged.
• maximum funding of $100,000 in direct costs (plus indirect costs).
• period of performance should not exceed 1 year.

career development award – letter of intent due april 6, 2021

• principal investigator:  independent investigators at the level of assistant professor, instructor, or equivalent; must be within 5 years of first faculty appointment (or equivalent)
• most not have received a career development award previously from any program within the congressionally directed medical research programs.
• must not have received more than $300,000 in total direct costs for previous or concurrent lung cancer research as a pi of one or more federally or privately funded, non-mentored, peer-reviewed grants.

mentor:  at or above the level of associate professor (or equivalent),

must have a strong publication and funding record in lung cancer research

• supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher.
• emphasis on research with high potential impact.
• clinical trials not allowed.
• career development plan is required with appropriate mentor guidance.
• preliminary data not required.
• military relevance strongly encouraged.
• maximum funding of $250,000 in direct costs (plus indirect costs).
• period of performance should not exceed 2 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for more information about the lcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507 
help@ebrap.org

the fy21 defense appropriations act is anticipated to provide funding to the department of defense ocrp to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, retirees, their family members, and all women impacted by this disease.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy21 ocrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.    

https://cdmrp.army.mil/funding/ocrp

investigator-initiated research award – pre-application due april 1, 2021

must be an independent investigator at or above the level of assistant professor (or equivalent).

partnering pi option:  
up to two investigators may collaborate on a single application, each of whom will be recognized as a principal investigator (pi) and receive a separate award. 

• supports meritorious basic and clinically oriented research in ovarian cancer.
• impact is an important review criterion.
• preliminary data are required.
• clinical trials are not allowed. 

pre-application is required; application submission is by invitation only.

• maximum funding of $600,000 for direct costs (plus indirect costs).
• maximum funding of $800,000 for direct costs (plus indirect costs) for partnering pi option.
• maximum period of performance is 4 years.

ovarian cancer academy award – early-career investigator – pre-application due april 1, 2021

must be within 5 years of his/her last postdoctoral research position (ph.d.) or clinical fellowship (m.d.), or equivalent as of the full application submission deadline.

a statement of eligibility is required.

• supports the addition of new early-career investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.
• early-career investigators whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• a designated mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.
• a designated mentor may only mentor one early-career investigator.
• the designated mentor is not required to be at the same institution as the early-career investigator.
• preliminary data are required.
• clinical trials are allowed.
• pre-application is required; application submission is by invitation only.
• maximum funding of $725,000 for direct costs (plus indirect costs).
• maximum period of performance is 4 years.

pilot award – pre-application is due april 1, 2021

investigators at or above the postdoctoral level (or equivalent).

• supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.
• innovation and impact are important review criteria.
• goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.
• clinical trials are not allowed.
• pre-application is required and blinded; application submission is by invitation only.
• maximum funding of $250,000 for direct costs (plus indirect costs).
• maximum period of performance is 2 years.

clinical translational research award - pre-application due april 1, 2021

must be an independent investigator at or above the level of assistant professor (or equivalent).

• supports translational research addressing high-impact or unmet needs in ovarian cancer.
• supports correlative studies related to or associated with planned, ongoing, or completed clinical trials supported by other funding sources. 
• emphasis on the utilization of precision medicine and computational approaches that identify individual tumor characteristics and predictive biomarkers across diverse groups to optimize patient care and outcomes.
• preliminary data are required.
• clinical trials are not allowed.
• pre-application is required; application submission is by invitation only.
  • maximum funding of $450,000 for direct costs (plus indirect costs).
  • maximum period of performance is 3 years.

proteogenomics research award – pre-application due april 1, 2021

must be at or above the level of postdoctoral fellow (or equivalent).

• supports the genomic and/or transcriptomic and/or proteomic analysis of currently available clinical specimens with a focus on answering biologic and pathophysiologic questions of clinical relevance in ovarian cancer.
• innovation and impact are important review criteria.
• analysis of clinical trial-derived specimens and/or large patient specimen cohorts is encouraged.
• clinical trials are not allowed.
• preliminary data are not required but are allowed.
• submission of a letter of intent is required prior to full application submission.
  • maximum funding of $250,000 for direct costs (plus indirect costs).
  • maximum period of performance is 2 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for more information about the ocrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507 
help@ebrap.org

description of the funding

eligible organizations can apply for up to $250,000 per year per project (with a maximum of $750,000 over 3 years). we will fund accessibility standards research projects that focus on one or more of the following priority areas:

• accessibility in indigenous communities
• built environment with a focus on heritage buildings
• communication, other than plain language
• design and delivery of programs and services
• information and communication technology
• procurement (buying) of goods, services and facilities

objective

this funding supports projects that:

• advance/ inform research on accessibility standards to help develop new or revise existing accessibility standards that fall under federal areas of responsibilities; 
• connect people with disabilities, other experts, and partners in the disability field and other fields to design and implement the research; and
• share findings of research, information, best practices and tools on accessibility barriers and standards.

the stratas foundation is the first volunteer not-for-profit organization dedicated to funding canadian mental health research by early career researchers. help us invest in new, innovative ideas by applying for funding below.

our selections committee will determine the winning candidate during the review period in march. the winner will be contacted following the review period.

the deadline to submit your application form for this $1,000 award is february 28, 2021 at 11:59 pm est.

note:

applicants should prepare the following documents ahead of time to complete the application:

- a 1-page research proposal + bibliography
- confirmation of enrollment or employment at a canadian university or research institute
- contact information
- names of investigators and co-investigators